ROCHE VERSED WHOLESALER PRICE INCREASED 9.5%
ROCHE VERSED WHOLESALER PRICE INCREASED 9.5% on July 1 for the most popular dosage, the 5 mg/ml 1 ml vial. A Roche Labs' notice sent to wholesalers July 1 cites higher prices for seven of the eight Versed (midazolam) dosage forms. The increases ranged from 9.5% to 19.5%. The last time Roche Labs raised Versed prices was eight months ago, in October 1990. The highest increase in Versed's average wholesale price was for a box of 10 Versed 5 mg/ml 10 ml multidose vials: $ 671.69 as of July 1. The prices for four other Versed dosages rose 14.9%, with the new prices ranging from $ 143.90 for 2 ml unit dose vials of 5 mg/ml to $ 346.70 for 5 ml multidose vials (both in boxes of 10). Of the 45 drugs included on Roche's price list, only three were not subject to price increases -- Roche's biggest seller, the hospital antibiotic Rocephin (ceftriaxone sodium); and the anti- cancer drugs Roferon-A (interferon alfa-2a); and fluorouracil. Other major Roche drugs with higher prices as of July 1 are Accutane, Bactrim and Bumex, which now cost wholesalers an additional 9.5%. The AWP for the 15 dosage forms of Valium is up 6%, as is the price for the non-barbiturate sedative Dalmane. Valium prices now range from $ 15.78 per 5 mg/ml 10 ml vial to $ 432.25 for 500 10 mg tablets. The top Dalmane price is $ 258.50 for 500 30 mg tablets.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth